Literature DB >> 17293111

Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker.

Scott C Jeffrey1, Minh T Nguyen, Ruth F Moser, Damon L Meyer, Jamie B Miyamoto, Peter D Senter.   

Abstract

The minor groove binder beta-glucuronide drug-linker 3 was constructed from amino CBI 1 and determined to be a substrate for Escherichia coli beta-glucuronidase (EC 3.2.1.31), resulting in facile drug release. Compound 3 was conjugated to mAbs cAC10 (anti-CD30) and h1F6 (anti-CD70) to give antibody-drug conjugates (ADCs) with potencies comparable to that of free drug 1. The ADCs were largely monomeric at intermediate loading levels (4-5drug/mAb), in contrast to highly aggregated p-aminobenzylcarbamate dipeptide-based ADCs of 1 previously reported. Significant levels of immunologic specificity were observed with cAC10-3 by comparing antigen positive versus negative cell lines and binding versus non-binding control ADCs. The water soluble beta-glucuronide linker is stable in plasma and effectively delivers drugs to target cells leading to potent cytotoxic activities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17293111     DOI: 10.1016/j.bmcl.2007.01.071

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  7 in total

1.  Expanded Utility of the β-Glucuronide Linker: ADCs That Deliver Phenolic Cytotoxic Agents.

Authors:  Scott C Jeffrey; Jef De Brabander; Jamie Miyamoto; Peter D Senter
Journal:  ACS Med Chem Lett       Date:  2010-06-14       Impact factor: 4.345

Review 2.  Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.

Authors:  Franco Dosio; Paola Brusa; Luigi Cattel
Journal:  Toxins (Basel)       Date:  2011-07-14       Impact factor: 4.546

Review 3.  Linkers Having a Crucial Role in Antibody-Drug Conjugates.

Authors:  Jun Lu; Feng Jiang; Aiping Lu; Ge Zhang
Journal:  Int J Mol Sci       Date:  2016-04-14       Impact factor: 5.923

Review 4.  Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems.

Authors:  Feng Jiang; Biao Liu; Jun Lu; Fangfei Li; Defang Li; Chao Liang; Lei Dang; Jin Liu; Bing He; Shaikh Atik Badshah; Cheng Lu; Xiaojuan He; Baosheng Guo; Xiao-Bing Zhang; Weihong Tan; Aiping Lu; Ge Zhang
Journal:  Int J Mol Sci       Date:  2015-10-09       Impact factor: 5.923

Review 5.  Antibody drug conjugate: the "biological missile" for targeted cancer therapy.

Authors:  Zhiwen Fu; Shijun Li; Sifei Han; Chen Shi; Yu Zhang
Journal:  Signal Transduct Target Ther       Date:  2022-03-22

Review 6.  The Chemistry Behind ADCs.

Authors:  Vesela Kostova; Patrice Désos; Jérôme-Benoît Starck; Andras Kotschy
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-07

Review 7.  Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics.

Authors:  Eunhee G Kim; Kristine M Kim
Journal:  Biomol Ther (Seoul)       Date:  2015-11-01       Impact factor: 4.634

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.